/
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnolo…
$26.78
+$0.17 (+0.64%)
Price from 32 days ago
The business is unprofitable at the operating level (-87.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 38.9% YoY with margins expanding 92.3pp.
Negative free cash flow of -$35M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$81M
▲ +38.9% YoY
Net Income (TTM)
-$103M
▲ +33.9% YoY
Op. Margin
-140.35%
▲ +92.3pp YoY
ROIC
-31.08%
▲ +2.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$77M
▲ +69.2% YoY
Op. Cash Flow (TTM)
-$75M
▲ +70.0% YoY
Net Debt
-$348M
Net Cash Position
Cash & Equiv.
$365M
5Y CAGR: +22.2%
Continue Research